Investigational drug · Phase 3
ION363
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ION363"
First trial start
2021
Jun 14, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ION363", any sponsor or status.
Conditions studied
As listed on its trial records.
- Amyotrophic Lateral Sclerosis
Approved drugs for the same conditions: ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ION363" as an intervention, largest first.
- FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)Pivotal-lookingActive, not recruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT04768972 · 89 participants · Start Jun 14, 2021 · Primary completion Jun 17, 2026
Drug: ION363; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: La Jolla, California; Palo Alto, California; Baltimore, Maryland · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeting fused in sarcoma (FUS): a novel antisense strategy for treating idiopathic pulmonary fibrosis.
Katariya BB, Chillappagari S, Arnold L, et al. · Signal Transduct Target Ther 2026
- Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.
Korben VA, Lyashchenko AK, Blanco-Redondo B, et al. · Nat Med 2022
Also in development for Amyotrophic Lateral Sclerosis
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- MN-166ibudilastPhase 31 trial
MediciNova · Amyotrophic Lateral Sclerosis
- CNMAu8gold nanocrystalsPhase 22 trials
Clene Nanomedicine · Amyotrophic Lateral Sclerosis, Multiple Sclerosis
- AMT-162Phase 21 trial
UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis
- AP-101Phase 21 trial
AL-S Pharma · Amyotrophic Lateral Sclerosis
- BIIB147Phase 21 trial
Biogen · Amyotrophic Lateral Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Ionis Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.